Israel Autoinjectors Market Overview

The Israel Autoinjectors Market was valued at USD 58.21 Million in 2025 and is projected to reach USD 174.04 Million by 2035, growing at a CAGR of 11.57%, up from USD 39.77 Million in 2020. Israel ranks sixth in the Middle East & Africa Autoinjectors Market report with an 11.2% regional share, behind the Rest of MEA grouping, Saudi Arabia, the United Arab Emirates, South Africa and the Other GCC Countries, and grows below the regional 12.53% — as a fully insured, high-penetration developed market with limited untreated headroom, its domestic trajectory resembles Western Europe's more than its neighbours'.

The Global Autoinjectors Market report is explicit that Israel's weight is on the supply side: Teva — whose SEC filings on SIMLANDI (adalimumab-ryvk, launched with Alvotech in the United States in May 2024) and SELARSDI, and on biosimilar device litigation, are cited throughout the report — anchors a domestic generics and biosimilar industry for which device presentation is a core competitive variable, giving the market industry significance far beyond its demand share. Alongside Teva sits Elcam Medical (Kibbutz Bar'am, Galilee), a cooperative-owned device manufacturer that entered the autoinjector field in 2006 and, through its E3D subsidiary, supplies disposable and reusable autoinjectors, on-body systems and connected devices — the Flexi-Q PFS, PDVR, DV, HV, EAI and CAI platforms — to pharma OEMs worldwide. Domestic demand runs through the Israel Ministry of Health, whose AMAR medical-device registration governs combination products and whose annual health-basket process decides which therapies — and presentations — the four national health funds must cover. This report quantifies the market across twelve segmentation axes and 27 segment tables with a dedicated four-zone analysis.

What Shapes the Israeli Market

1. A biosimilar exporter whose devices are litigated. Teva's SIMLANDI and SELARSDI presentations — and the device-patent disputes around them the report tracks through SEC filings — show that for a biosimilar company the autoinjector is not packaging but the competitive product itself: interchangeability, human-factors validation and freedom-to-operate on the device decide whether a biosimilar can launch at all. Israel is where that strategy is directed, so its device decisions ripple through the U.S. and European biosimilar markets the report analyses.

2. Elcam's OEM device tier. E3D's Flexi-Q family gives Israel a rare thing in the Middle East — a domestic autoinjector platform maker serving global pharma OEMs with precision moulding, automated assembly and cleanroom manufacturing, plus connected and on-body variants. The report profiles Elcam in its device-manufacturer chapter and lists E3D among the competitors of Ypsomed, SHL Medical, Nemera and Crossject.

3. Universal coverage through four health funds and the health basket. Every resident belongs to one of four national health funds (Clalit, Maccabi, Meuhedet, Leumit) that must cover the therapies in the annual health basket; each basket update is a national inclusion decision for biologics, biosimilars and GLP-1s, and the funds negotiate centrally with strong bargaining power — the report reads Israel as a formulary-driven, price-transparent market in which premium device features (connectivity at 13.82% CAGR across MEA, SmartPilot-type; reusable systems at 13.62%) clear on demonstrated benefit and where a digitally advanced population adopts them early. Celltrion, Samsung Bioepis and Fresenius Kabi compete with Teva's own presentations in fund tenders.

Israel Autoinjectors Market by Zone — In-Depth Analysis

Israel's autoinjector market is small in area but sharply layered: demand concentrates in the Tel Aviv metropolitan area, supply sits in the Galilee and the central pharmaceutical belt, and an export channel dwarfs domestic consumption. The zone view reads each against the report's drivers.

How the zone analysis is used in the report. The four-zone view maps Israel's revenue lines from the 27 segment tables onto health-fund central negotiation, basket-committee decisions, peripheral-access gaps and the Teva–Elcam supply footprint, so that a biosimilar company can see how device presentation decides launch, a device OEM where E3D competes, and a pharma partner where each modality's prescribing base sits. Quantified sub-national revenue splits (by district, by health fund, or domestic-versus-export) are available as a customization of this report — request the zone data cut here.

Israel Segment Insights

Growth rates shown are the Middle East & Africa values from the report's regional segment tables; Israel's own trajectory (11.57%) runs below them because it starts from a fully insured, high-penetration base. Israel's distinctive mix is its antibody and biosimilar weighting, its early adoption of reusable and connected platforms, and a supply-side role — Teva's presentations and Elcam's OEM devices — that dwarfs its 11.2% revenue share.

Market Drivers and Restraints in Israel

• Driver — supply-side weight. Teva's biosimilar autoinjector presentations (SIMLANDI, SELARSDI) and device litigation strategy; Elcam Medical / E3D Flexi-Q OEM platforms — industry significance beyond demand share.
• Driver — universal coverage and the health basket. Four health funds with central negotiation; annual basket inclusion of biologics, biosimilars and GLP-1s (WHO Essential Medicines List) moves national demand in steps.
• Driver — digitally advanced, ageing population. Early adoption of connected (SmartPilot-type) and reusable platforms; the WHO ageing driver; IV-to-SC conversion via KEYTRUDA QLEX (Merck) and Enable Injections enFuse at Sheba, Rambam and Hadassah.
• Driver — global platform and biosimilar competition. Ypsomed, SHL Medical, Owen Mumford, Gerresheimer and Haselmeier serve the multinational base of Novo Nordisk, Eli Lilly, Sanofi, AbbVie and AstraZeneca; Celltrion, Samsung Bioepis and Fresenius Kabi compete with Teva in fund tenders.
• Restraint — health-fund bargaining power. Central tendering compresses device economics and confines premium features to supplementary insurance until basket inclusion.
• Restraint — small, saturated domestic base. Limited untreated headroom; growth depends on mix rather than volume.
• Restraint — AMAR registration and geopolitical supply risk. Local device registration adds qualification steps; regional instability affects logistics and clinical-trial continuity.

Competitive Landscape

Israel's competitive structure is defined by its two domestic champions — Teva (biosimilar and generic presentations, epinephrine autoinjector generics) and Elcam Medical / E3D (Flexi-Q OEM autoinjectors, on-body and connected devices) — alongside the global platform specialists Ypsomed, SHL Medical, Owen Mumford / embecta, Gerresheimer, Haselmeier, Nemera and Crossject. Pharma platform users include Novo Nordisk, Eli Lilly, Sanofi, AbbVie, Pfizer, AstraZeneca, Johnson & Johnson, UCB and Roche; biosimilar competitors include Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris and Sandoz; BD, West Pharmaceutical Services, SCHOTT Pharma, Nipro and Terumo anchor primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — Israel

Key Questions Answered

• How large is the Israel autoinjectors market and why does its industry significance exceed its 11.2% MEA share?
• How do Teva's SIMLANDI and SELARSDI presentations — and the biosimilar device litigation the report tracks — show that the autoinjector is the competitive product for a biosimilar company?
• Where does Elcam Medical's E3D Flexi-Q OEM platform family sit against Ypsomed, SHL, Nemera and Crossject?
• How do the four health funds, central tendering and the annual health-basket process decide which presentations reach Israeli patients?
• Which zones carry the deepest demand, and which global platform specialists and biosimilar competitors are best positioned in a fully insured, digitally advanced market?

This country report is drawn from the Global Autoinjectors Market report. Related coverage: Middle East & Africa Autoinjectors Market report, Saudi Arabia, United Arab Emirates, Other GCC Countries, North America, United States, Canada, Mexico, Europe, Germany, United Kingdom, France, Italy, Spain, Benelux, Switzerland & Austria, Nordic Countries, Central & Eastern Europe, Asia-Pacific, China, Japan, South Korea, India, Australia & New Zealand, Southeast Asia, Latin America, Brazil, Argentina, Colombia and Chile autoinjectors market reports.